In the combined T1 cohort (durvalumab 10–20 mg/kg plus tremelimumab 1 mg/kg), the combination was effective regardless of PD-L1 expression; ORR was 22%(95% CI, 3–60) in patients with PD-L1 positive tumors (≥25% of tumor cells with membrane staining for PD-L1) and 29% (95% CI, 8–58) in PD-L1 negative patients, including patients with no PD-L1 staining [52]. Here, CD274 is linked to neoplasm.